MO34-3 The efficacy of combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy for PD-L1-positive EGFR-mutant NSCLC: NJLCG2202
Title:
MO34-3 The efficacy of combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy for PD-L1-positive EGFR-mutant NSCLC: NJLCG2202
Author:
Kawashima, Y. Inomata, M. Saito, R. Morinaga, D. Nogawa, H. Satou, M. Suzuki, Y. Yanagisawa, S. Kikuchi, T. Jingu, D. Yoshimura, N. Harada, T. Miyauchi, E.